CD44 and breast cancer: Available in vitro data, however, appears to confirm that the degree of intrinsic plasticity to drive the trastuzumab-refractory CD44+/CD24−/low mesenchymal CSC state may account for the de novo resistance to trastuzumab in basal/cHER2+ BC.